Inhibrx says combo therapy shrank more tumors than Merck's Keytruda alone
San Diego-based biotech Inhibrx is claiming that it outperformed Merck’s Keytruda in a difficult-to-treat cancer. The combination of Keytruda and Inhibrx’s experimental drug INBRX-106 shrank more tumors than Keytruda alone in patients with metastatic head ...
May 11, 2026 10:51 AM EDT R&D Inhibrx says combo therapy shrank more tumors than Merck's Keytruda alone Max Gelman Senior Editor San Diego-based biotech Inhibrx is claiming that it outperformed Merck’s Keytruda in a difficult-to-treat cancer. The combination of Keytruda and Inhibrx’s experimental drug INBRX-106 shrank … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that